MNC年报扫描|“明星”产品替尔泊肽营收大增 礼来能否在GLP-1竞赛中称霸?

21世纪经济报道
07 Feb

2月6日,礼来发布2024年第四季度及全年业绩报告。报告显示,2024年第四季度营收为135.3亿美元,同比增长45%;净利润为44.1亿美元,同比增长101%。2024年全年营收为450.4亿美元,同比增长32%;净利润为105.9亿美元,同比增长102%。  从具体的产品看,礼来的“明星”产品替尔泊肽推动了其收入的增长。去年第四季度,降糖版替尔泊肽Mounjaro销售额为35.3亿美元,同比...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10